Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study

Flores, Estefanía; Mbachi, Chimezie; Achebe, Ikechukwu; Asotibe, Jennifer C; Palomera-Tejeda, Emmanuel; Vohra, Ishaan; Udechukwu, Victor; Kotwal, Vikram

doi:10.1007/s00384-020-03775-9

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is recognized as the most severe condition that can give rise to IBD-related complications . Many reports have suggested that prolonged intestinal inflammation greatly increases the risk of developing CRC. , Patients with inflammation-associated CRC tend to have worse outcomes . Progression from colitis to CRC is a continuous dynamic process and is often accompanied by dysbiosis and a compromised gut barrier. , …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme

Xin

Zheng

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

Fucoidan has many biological activities, including the inhibitory effect on the development of various cancer types. This study showed that lipopolysaccharide-induced inflammation in FHC cells (normal human colonic epithelial cells) could be reversed using fucoidan at different concentrations. The fucoidan-induced anti-inflammatory effect was also confirmed through in vivo experiments in mice. Compared to the mice of the model group, the ratio of Firmicutes/Bacteroidetes in feces increased and the diversity of gut microbial composition was restored in mice after fucoidan intervention. In colorectal cancer (CRC) cells DLD-1 and SW480, fucoidan inhibited cell proliferation and promoted cell apoptosis. It also blocked the cell cycle of DLD-1 and SW480 at the G0/G1 phase. The animal model of inflammation-related CRC showed that the incidence of tumors in mice was significantly reduced by fucoidan intervention. Furthermore, the administration of fucoidan decreased the expression levels of inflammatory factors such as TNF-α IL-6 and IL-1β in the colonic tissues. Therefore, fucoidan can effectively prevent the development of colitis-associated CRC.

show abstract

Section: Introductionmentioning

confidence: 99%

“…8,9 Patients with inflammation-associated CRC tend to have worse outcomes. 10 Progression from colitis to CRC is a continuous dynamic process and is often accompanied by dysbiosis and a compromised gut barrier. 11,12 The intestinal microflora is a highly complicated community comprising mainly of bacteria, viruses, fungi, and archaea.…”

Section: ■ Introductionmentioning

confidence: 99%

Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme

Xin

Zheng

et al. 2022

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…These data also suggest aggressiveness of CRC in CD patients, with at least 6 out of 13 participants having metastatic disease at the time of diagnosis (two participants were of unknown stage). The prognostic outcomes of CRC in IBD patients have also been variably reported in the literature, with the majority showing worse survival outcomes for CRC in IBD patients [26][27][28]. Recent data have also suggested that patients with CD colitis have more advanced tumour stages and a histologically more aggressive cancer type [27,29].…”

Section: Discussionmentioning

confidence: 99%

The long‐term incidence of dysplasia and colorectal cancer in a Crohn’s colitis population‐based cohort

et al. 2021

View full text Add to dashboard Cite

Aim The risk of developing colorectal cancer (CRC) in Crohn's disease (CD) has been variably reported. Chronic inflammation is associated with an increased risk of neoplasia; variable outcomes in CD possibly reflect the heterogeneous nature of the disease. The aim of this work was to characterize the risk of CRC in a New Zealand population‐based cohort of CD patients with colonic inflammation. Method A review of all participants with CD in the population‐based Canterbury Inflammatory Bowel Disease Study was conducted. Data on demographics, endoscopic surveillance, presence of dysplasia/neoplasia and oncological outcome were extracted. The age‐adjusted standardized incidence ratio (SIR) was used to compare the incidence of CRC in the cohort with the incidence of CRC in the New Zealand population in 2006. Results Data on 649 patients with CD were collected. Four hundred and thirty‐six participants (58% female) with ileocolonic or colonic CD were included for analysis. CRC was diagnosed in 13 patients (62% female). The median age at CRC diagnosis was 58.5 years, and the mean duration of CD prior to diagnosis of CRC was 20.4 years. When compared with the New Zealand population (using census data), the overall age‐adjusted SIR was 4.1 (95% CI 2.4–7.1). Conclusion This population‐based cohort of patients with colonic CD shows a significantly increased risk of CRC compared with the general population. This is consistent with the colonic location of inflammation increasing the risk of neoplasia. Inclusion of patients with isolated upper gastrointestinal/ileal CD in similar studies may mask the truly increased risk for patients with long‐standing colonic inflammation.

show abstract

Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study

Cited by 2 publications

References 26 publications

Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme

Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme

The long‐term incidence of dysplasia and colorectal cancer in a Crohn’s colitis population‐based cohort

Contact Info

Product

Resources

About